Dear Members,
Quick Heal Technologies Limited
The Board of Directors of your Company is pleased to present the 29th
Annual Report along with the audited financial statements, for the financial year ended
March 31, 2024.
1. FINANCIAL RESULTS:
( in Crores)
Particulars |
Consolidated |
Standalone |
2023-2024 |
2022-2023 |
2023-2024 |
2022-2023 |
Revenue from Operations (Net) |
291.75 |
278.09 |
291.75 |
278.11 |
Other Income |
21.39 |
22.13 |
21.37 |
22.38 |
Total Income |
313.14 |
300.22 |
313.12 |
300.49 |
Expenses |
274.33 |
276.21 |
274.48 |
275.31 |
Depreciation |
12.60 |
15.99 |
12.60 |
15.99 |
Total Expenditure |
286.93 |
292.20 |
287.08 |
291.30 |
Profit Before Tax |
26.21 |
8.02 |
26.04 |
9.29 |
Total Tax |
1.97 |
1.62 |
1.97 |
1.59 |
Profit After Tax |
24.24 |
6.40 |
24.07 |
7.70 |
The abovementioned figures are extracted from financial statements
prepared in accordance with the Indian accounting standards (IND AS).
The Standalone and Consolidated Financial Statements of the Company for
the financial year 2023-24 are prepared in compliance with the applicable provisions of
the Companies Act 2013 (the Act') including Indian Accounting Standards
specified under section 133 of the Act. The audited Standalone and Consolidated Financial
Statements together with the Auditors' Report thereon forms part of the Annual Report
of the financial year 2023-24. The Auditors' Report on Standalone and Consolidated
financials is unmodified.
2. COMPANY PERFORMANCE OVERVIEW AND OUTLOOK
Your Company recorded a total income of 313.14. Crores for the
financial year 2023-24 as against
300.22 Crores in 2022-23, resulting in an increase of 4.30% in the
total income during the year under review on consolidated basis. The Profit after Tax of
the Company was increased by 278.8% from 6.40 Crores in the year 2022-23 to 24.24
Crores in the year under review.
Outlook of the business has been discussed in detail in the "Management
Discussion and Analysis" which forms a part of this Annual Report.
3. DIVIDEND
The Board of Directors of your Company have recommended a final
Dividend @ 30% i.e. 3/- per fully paid up equity shares of 10 each, for the financial
year
2023-24. The payment of aforesaid Dividend is subject to the approval
of the Members at the ensuing Annual General Meeting.
The total dividend for the financial year 2023-24 would involve a total
outflow of 16.05 crores resulting in a dividend pay-out ratio of 66.68.% of the
standalone profits of the Company.
In view of the changes made under the Income Tax Act, 1961, by the
Finance Act, 2020, the dividends paid or distributed by the Company shall be taxable in
the hands of the shareholders. The Company shall, accordingly, make the payment of the
final dividend after deduction of tax at source.
The dividend recommended for the financial year 2023- 24, is in
compliance with the Dividend Distribution Policy in terms of regulation 43A of the
Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (SEBI LODR). The Dividend Distribution Policy of the Company is also
hosted on the website of the Company and can be viewed at
https://www.quickheal.co.in/documents/ investors/Dividend-Distribution-Policy-21.pdf.
4. TRANSFER OF PROFITS TO RESERVES
Your directors have decided not to transfer any amount to the General
Reserve and to carry forward the entire surplus under the Statement of Profit & Loss.
5. PUBLIC DEPOSITS
During the year under review, your Company did not accept any deposits
under section 73 and 74 of the Companies Act, 2013 read with the Companies (Acceptance of
Deposits) Rules, 2014, as amended from time to time.
6. REPORT ON PERFORMANCE OF SUBSIDIARIES
The Company has two subsidiaries as of March 31, 2024. There are no
associates or joint venture companies within meaning of Section (2)(6) of the Companies
Act, 2013. There has been no material change in the nature of the business of the
subsidiaries.
A statement containing salient features of the financial statements of
subsidiary Companies in Form AOC-1, as required under section 129 (3) of the Companies
Act, 2013, forms a part of this Board's Report and is annexed as Annexure A. The
audited financial statements in respect of each of the subsidiaries shall be kept open for
inspection at the Registered Office of the Company on all working days between 11.00 a.m.
to 1:00 p.m. up to the date of the forthcoming AGM. Further, the Company will make
available the audited annual accounts and related information about the subsidiary
companies, upon request by any Member of the Company.
7. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A)
As per the provisions of Regulation 34 of the SEBI LODR a detailed
review by the Management of the business operations of the Company is presented under
separate section "Management Discussion and Analysis" (MD&A) which forms a
part of this Annual Report. The MD&A Report captures your Company's performance,
industry trends and other material changes with respect to your Company.
8. CORPORATE GOVERNANCE REPORT
Your Company believes in adopting the best practices of corporate
governance. The Company has complied with the regulatory provisions for Corporate
Governance as prescribed under Schedule V of SEBI LODR. The quarterly Corporate Governance
Reports are submitted to the stock exchanges in compliance with the regulatory provisions.
A certificate from M/s
J. B. Bhave & Co., Practicing Company Secretaries, confirming
compliance with the conditions of the Corporate Governance, forms a part of this Annual
Report.
9. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT
A Business Responsibility and Sustainability Report as per Regulation
34 of the SEBI LODR, detailing the various initiatives taken by the Company on the
environmental, social and governance front forms an integral part of this Annual Report.
10. INTERGATED REPORT
The Company has provided an Integrated Report which encompasses both
financial and non-financial information to enable the Members to take well- informed
decisions and have a better understanding of the Company's long-term perspective. The
Report also touches upon aspects such as organization's strategy, governance
framework, performance and prospects of value creation based on the six forms of capital
viz. financial, service, intellectual, human, social & relationship and natural
capital.
11. RISK MANAGEMENT
The Company hasput in place a robust risk management framework which
facilitates the identification of risks and also mitigation thereof. The Audit Committee
and Risk Management Committee are updated on the risks on a quarterly basis. There are no
risks which in the opinion of your board threaten the existence of the Company. However,
risks that may pose a concern, are explained under Management Discussion and Analysis
which forms part of this Annual Report.
12. MATERIAL CHANGES AND COMMITMENTS AFFECTING FINANCIAL POSITION
BETWEEN THE END OF THE FINANCIAL YEAR AND DATE OF THE REPORT
There have been no other material changes and commitments which affect
the financial position of the Company that have occurred between the end of the financial
year to which the financial statements relate and the date of this report.
13. LISTING ON STOCK EXCHANGES
The Company's shares are listed on BSE Limited and
the National Stock Exchange of India Limited.
14. COMPLIANCE WITH THE CODE OF CONDUCT
A declaration signed by the Managing Director affirming compliance with
the Company's Code of Conduct by the Directors and Senior Management Personnel, for
the financial year 2023-24, as required under Schedule V of the SEBI LODR forms a part of
this Annual Report.
15. DIRECTORS & KEY MANAGERIAL PERSONNEL (KMPS)
a. Composition of Board & Details of KMPs
As on March 31, 2024, the Board comprised of two Executive Directors,
four Non-Executive Independent Directors and one Non-Executive Director. The Board is well
diversified and consists of one Women Independent Director.
Mr. Kailash Katkar, Managing Director, Mr. Sanjay Katkar, Joint
Managing Director, Mr. Vishal Salvi, Chief Executive Officer (CEO), Mr. Ankit Maheshwari,
Chief Financial Officer (CFO) and Mr. Sarang Deshpande, Company Secretary (CS) are the Key
Managerial Personnel of the Company within the meaning of sections 2(51) and 203 of the
Companies Act, 2013 read together with the Companies (Appointment & Remuneration of
Managerial Personnel) Rules, 2014.
b. Appointment & Cessation during the year:
Mr. Sanjay Katkar (DIN: 00397277, Joint Managing Director of the
Company, retires by rotation at the ensuing AGM and, being eligible, offers himself for
re- appointment. A Profile of Mr. Sanjay Katkar, as required by Regulation 36(3) of the
SEBI LODR will be given in the Notice convening the forthcoming AGM.
The term of appointment of Mr. Amitabha Mukhopadhyay as an independent
non executive director is expiring on June 9, 2024, however Board of Directors in their
meeting held on April 25, 2024 had appointed him as an additional director and renewed his
term as an independent director for another period of 5 years i.e. up to June 10, 2029
subject to approval through special resolution at the ensuing annual general meeting.
Mr. Kailash Katkar resigned as CEO and continued as Managing Director
w.e.f. July 3, 2023
Mr. Vishal Salvi appointed as CEO of the Company
w.e.f. July 3, 2023.
Mr. Navin Sharma resigned as CFO w.e.f. April 18, 2023 and Mr. Ankit
Maheshwari appointed as CFO
w.e.f. April 26, 2023
Mr. Srinivas Rao resigned as Company Secretary
w.e.f. July 17, 2023 and Mr. Sarang Deshpande appointed as Company
Secretary w.e.f. October 26, 2023.
Mr. Vinav Agarwal resigned as Compliance officer w.e.f. September 15,
2023 and Mr. Vikram Dhanani appointed as Compliance Officer w.e.f. October 26, 2023.
c. Policy on Director's Appointment and
Remuneration
The details including the composition and terms of reference of the
Nomination and Remuneration Committee and the meetings thereof held during the Financial
Year and the Remuneration Policy of the Company and other matters provided in Section
178(3) of the Act are given in the Report on Corporate Governance section forming part of
this Annual Report.
The Policy for appointment of a new director on the board is available
on Company's website at https://www.quickheal.co.in/
documents/investors/policies/Nomination_and_ Remuneration_Policy.pdf
16. BOARD AND ITS COMMITTEE'S MEETINGS
During the financial year 2023-24, six Board meetings were held. The
maximum time gap between any two meetings did not exceed the prescribed period of one
hundred twenty days. The details of the attendance of Directors at the Board Meetings and
Committees Meetings such as Audit Committee, Nomination and Remuneration Committee,
Stakeholders Relationship Committee, Risk Management Committee and Corporate Social
Responsibility Committee are given in the Corporate Governance Report which forms part of
this Report.
17. DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to Section 134(5) of the Companies Act, 2013, the Board of
Directors of your Company to the best of their knowledge and ability hereby state and
confirm that:
a) In the preparation of the annual accounts for the year ended March
31, 2024, the applicable accounting standards have been followed along with proper
explanation relating to material departures.
b) They have selected such accounting policies and applied them
consistently and made judgments and estimates that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the company at the end of the
financial year and of the profit of the company for the same period.
c) They have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the
provisions of the Companies Act, 2013 for safeguarding the assets of the company and for
preventing and detecting fraud and other irregularities;
d) The annual accounts have been prepared on a going concern basis;
e) Proper internal financial controls have been laid down in the
company that are adequate and were operating effectively.
f) Proper systems to ensure compliance with the provisions of all
applicable laws have been devised and such systems are adequate and are operating
effectively.
18. DECLARATION OF INDEPENDENCE BY INDEPENDENT DIRECTORS
The Company has received necessary declarations from each Independent
Director under section 149(7) of the Companies Act, 2013 that he/she fulfils the criteria
of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 25
of SEBI LODR.
The Independent Directors have complied with the Code for Independent
Directors prescribed in Schedule IV to the Act and the Code of Conduct for Directors and
senior management personnel of the Company.
Based on the confirmations/disclosures received from the Directors
under Section 149(7) of the Companies Act 2013 and on evaluation of the relationships
disclosed, the following Non-Executive Directors are considered as Independent Directors:
a. Mr. Amitabha Mukhopadhyay
b. Ms. Apurva Joshi
c. Mr. Bhushan Gokhale
d. Mr. Richard Stiennon
19. BOARD EVALUATION
The Board has established a comprehensive process to evaluate the
performance of the Board, its Committees and of individual directors. The performance
evaluation matrix defining the criteria of evaluation for each of the above has been put
in place. The performance evaluation of the Independent Directors was carried out by the
other members of the Board (excluding the Director being evaluated). A meeting of the
Independent Directors was held on March 26, 2024, to review the performance of
Non-Independent Directors and the Board as a whole. The Chairperson of the Nomination
& Remuneration Committee had updated the other members of the Board about the outcome
of the evaluation process.
20. SUCCESSION PLANNING
Your Company have an effective mechanism for succession planning which
focuses on orderly succession of board members and other senior management team. The
Nomination and Remuneration Committee implements this mechanism, with the help of P&C
and in concurrence with the Board.
This process for senior management was initiated by defining the unique
roles by differentiating competencies. The next step was key role identification and
succession planning design where certain key business roles were identified which will
enhance organizational performance and provides long term competitive advantage. Now we
are in the completing stage of final step i.e identification of successors and by
providing required training to those successors so as to build leadership capabilities
across all business units and mitigating risk of loss of experienced leadership.
21. COMMITTEES OF THE BOARD
During the year under review, the composition of different Committees
of your Board of Directors is given hereunder:
Sr. No. |
Committee |
Composition |
1 |
Audit Committee |
Mr. Amitabha Mukhopadhyay
(Chairperson) |
Mr. Sanjay Katkar |
Mr. Bhushan
Gokhale |
Ms. Apurva
Joshi |
2 |
Nomination and Remuneration
Committee |
Ms. Apurva Joshi (Chairperson) |
Mr. Kailash Katkar |
Mr. Amitabha
Mukhopadhyay |
- |
3 |
Stakeholders Relationship
Committee |
Mr. Bhushan Gokhale
(Chairperson) |
Mr. Kailash Katkar |
Mr. Amitabha
Mukhopadhyay |
Ms. Apurva
Joshi |
4 |
Risk Management Committee |
Ms. Apurva Joshi
(Chairperson) |
Mr. Kailash Katkar |
Mr. Sanjay Katkar |
- |
5 |
CSR Committee |
Ms. Apurva Joshi (Chairperson) |
Mr. Kailash
Katkar |
Mr. Sanjay Katkar |
- |
22. SECRETARIAL AUDIT REPORT
As required by Section 204 of the Companies Act, 2013 and Rules made
thereunder, the Board appointed M/s. J B Bhave & Co., Practicing Company Secretaries,
Pune as the Secretarial Auditors of the Company for the financial year 2023-24. There are
no qualifications/ observations/ remarks in the Secretarial Audit Report for the year
ended March 31, 2024. The Secretarial Auditor has not reported any fraud during the
financial year.
EXPLANATION ON SECRETARIAL AUDITORS REPORT.
The Secretarial Auditors Report are self-explanatory and therefore do
not call for any separate or further comments or explanations.
The Secretarial Auditor's Report forms part of this
Annual Report, annexed as Annexure B.
23. STATUTORY AUDITORS
M/s MSKA & Associates, Chartered Accountants (Firm Registration No.
105047W), were appointed by the Shareholders at the 24th AGM held on July 15, 2019, as
Statutory Auditors for a term of five consecutive years to hold office until conclusion of
ensuing 29th AGM. The Board of directors in its meeting held on April 25, 2024, has
recommended re-appointment of M/s MSKA & Associates, Chartered Accountants (Firm
Registration No. 105047W) for term of 5 years accordingly, the Notice of ensuing 29th AGM
would include the proposal for re-appointment of Statutory Auditors.
EXPLANATION ON AUDITORS REPORT STATUTORY AUDITOR.
The notes to the accounts referred to in the Auditors Report are
self-explanatory and therefore do not call for any separate or further comments or
explanations.
24. INTERNAL AUDITORS
The Board has appointed M/s. Protiviti India Member Private Limited, as
Internal Auditors of the Company for the financial year 2024-25.
25. REMUNERATION OF DIRECTORS, KEY MANAGERIAL PERSOANNEL AND SENIOR
MANAGEMENT
As required under Section 197 (12) of the Act read with Rule 5 of
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement
showing details of personnel drawing remuneration in excess of the prescribed limit under
the said rules, are annexed as Annexure C' to this Boards' Report. The
Statement containing names of top ten employees, in terms of remuneration drawn and the
particulars of employees as required under section 197 (12) of the act read with Rule 5(2)
and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules
2014 is provided in a separate statement. In terms of proviso to Section 136(1) of the
Act, the Report and Accounts are being sent to the members excluding the aforesaid
Annexure. The said Statement is also open for inspection at the registered office up to
the date of the ensuing Annual General Meeting. Any Member interested in obtaining a copy
of the same may write to the Company Secretary.
The managerial remuneration paid to Executive Directors for the
financial year 2023-24 is in excess of the limits prescribed under the Act and SEBI LODR.
Accordingly, the Board of Directors have recommended the same for approval of the
shareholders.
26. EMPLOYEE STOCK OPTION SCHEME
Your Company has two Employee Stock Option Plans namely, Employees
Stock Option Scheme 2014 and Employees Stock Option Scheme 2021 for granting Term based
and performance-based Stock Options to Employees.
The above schemes are in line with the Securities and Exchange Board of
India (Share Based Employee Benefits) Regulation, 2021 ("SBEB Regulations").
The Company has obtained a certificate from the Secretarial Auditors of the Company
stating that the Schemes have been implemented in accordance with the SBEB Regulations and
the resolutions passed by the members. The certificates are available for inspection by
members in electronic mode. The details as required to be disclosed under the SBEB
Regulations can be accessed at https://www. quickheal.co.in/investors.
During the year under report, no employee has been granted stock
options, equal to or exceeding 1% of the issued capital (excluding outstanding warrants
and conversions) of your Company. The details of activities under the scheme have been
summarized in the Notes forming part of Financial Statements and annexed as Annexure D.
27. SECRETARIAL STANDARDS
During the financial year under review, the Company has followed the
applicable Secretarial Standards.
28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO
Particulars required to be furnished under the Companies (Disclosure of
Particulars in the Report of Board of Directors) Rules, 1988 are as under:
( in Crores)
Particulars |
Year ended March 31,
2024 |
Year ended March 31,
2023 |
Total foreign exchange outgo |
5.44 |
8.29 |
Total foreign exchange earnings |
18.53 |
15.42 |
29. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS
a. Energy Conservation
Company installed 45KW solar plant at its R&D centre located at
Thube Park, Shivaji Nagar, Pune. The plant generated 6.42% of its total energy requirement
for said R&D centre.
Policy benefits:- Company is availing lower electricity tariff
& electricity duty exemption under Maharashtra IT policy.
b. Technology Absorption, Adaptation and Innovation
The Company continues to use the latest technology for improving the
productivity and quality of its products and services and also focuses on innovation and
protecting consumers around the world with the latest technology. Few of the steps taken
are provided below:
1) Conduct Innovation Week involving team members across locations.
2) Promote and fund team members to represent & participate in
Technology Summits, research conferences and hackathons.
3) Induct interns from IITs and other top tier
academic institutes to explore new areas
4) Enable team members with AI/ML, GenAI, etc trainings from new
generation companies such as AWS, Microsoft, etc
5) Provide lab environment to explore use
cases on Gen AI
c. Foreign Exchange earnings and outgo:
Total foreign exchange earnings and outgo for the
financial year were as follows:
There are no Loans, Guarantees and Investments
provided by the Company as on March 31, 2024.
30. RELATED PARTY TRANSACTIONS
All related party transactions carried out during the year were carried
out on an arm's length basis and in the ordinary course of business. There were no
materially significant related party transactions with the Company's Promoters,
Directors, Management or their relatives, which could have had a potential conflict with
the interests of the Company.
All transactions with related parties were approved by the Audit
Committee and the Board of Directors. The particulars of contracts entered into during the
year are given in Form AOC-2 enclosed as Annexure E.
31. CORPORATE SOCIAL RESPONSIBILITY ('CSR'')
Your Company has a strong commitment to the society we live in. Your
Company has chosen Quick Heal Foundation' and implements its CSR objects
through the Foundation. The Company strives to promote Cybersecurity awareness, promotion
of education and community development. The Company's CSR policy is available on our
website at https://www.quickheal. co.in/investors/company-policies.
During the year under review, the Company spent a total of 1.82
Crores on CSR activities, vis-?-vis 1.71 Crores i.e. 2% as per provisions of the
Section 135 of the Companies Act, 2013. The Company continues to remain committed towards
undertaking CSR activities for the welfare of society.
A detailed report on CSR activities of your Company under the
provisions of the Companies Act, 2013 during the financial year 2023-24 is given as
Annexure F.
32. ADEQUACY OF INTERNAL FINANCIAL CONTROLS
The Board of Directors of your Company are responsible for ensuring
that the Internal Financial Controls ("IFC") are laid down in the Company and
that such controls are adequate and are operating efficiently and effectively. The
Company's IFC policies are commensurate with its requirements and are operating
effectively. The IFC covered the policies and procedures adopted by the Company for
ensuring orderly and efficient conduct of business including adherence to the
Company's policies, safeguarding of the assets of the Company, prevention and
detection of fraud and errors, accuracy and completeness of accounting records and the
timely preparation of reliable financial information.
33. VIGIL MECHANISM/WHISTLE BLOWER POLICY
The Company has a well laid down Vigil Mechanism/ Whistle Blower
Policy, details of which are given in the Report on Corporate Governance forming a part of
this Annual Report. The Company has also uploaded the said Whistle Blower Policy on its
website at https:// www. quickheal.co.in/investors/company-policies.
34. INVESTOR EDUCATION AND PROTECTION FUND
In accordance with the provisions of Sections 124 and 125 of the Act
and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules,
2016 ("IEPF Rules"), dividends of a company which remain unpaid or unclaimed for
a period of seven years from the date of transfer to the Unpaid Dividend Account shall be
transferred by the company to the Investor Education and Protection Fund
("IEPF"). In terms of the foregoing provisions of the Act, 1,32,095 dividend
amount and 1719 number of shares were transferred to the IEPF by the Company during FY
2023-24.
35. OTHER MATTERS
Your Directors state that during the financial year under review -
i. Neither the Managing Director nor the Whole- time Director of the
Company received any remuneration or commission from any of its subsidiaries.
ii. No significant or material orders were passed by the Regulators or
Courts or Tribunals which impact the going concern status and the Company's
operations in future.
iii. No fraud has been reported by the Auditors to the Audit Committee
or the Board under section 134(3).
iv. There is no change in the nature of the business of the Company.
v. There is no proceeding pending under Insolvency and Bankruptcy Code,
2016
vi. There is no instance of one-time settlement with any Bank or
Financial Institution.
vii. Change in name of premises wherein registered office of the
Company is situated from "Marvel Edge" to " Solitaire Business Hub"
36. ANNUAL RETURN
Pursuant to Section 92(3) of the Act, the Annual Return as on March 31,
2023 is available on Companies website on https://www.quickheal.co.in/documents/
investors/quick-heal-annual-returnt-2023.pdf
37. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013
The Company has in place an Anti-Sexual Harassment Policy in line with
requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and
Redressal) Act, 2013. All employees (permanent, contractual, temporary, trainees) are
covered under this policy. Internal Committee(s) has been set up across all its required
locations in India to address complaints received regarding sexual harassment. There were
no complaints reported during the financial year 2023-24.
38. APPRECIATION
Your Board places on record sincere gratitude and appreciation for all
the employees, customers, vendors, investors, bankers, end users, dealers, distributors,
business partners and other business constituents during the year under review. We also
thank the support received from various government and regulatory authorities.
For and on the behalf of the Board of Directors |
Quick Heal Technologies Limited |
Sd/- |
Sd/- |
Kailash Katkar |
Sanjay Katkar |
Chairman & Managing Director |
Joint Managing Director |
(DIN: 00397191) |
(DIN: 00397277) |
Place: Pune |
|